A vaccine developed at The Scripps Research Institute (TSRI) to block the “high” of heroin has proven effective in non-human primates. This is the first vaccine against an opioid to pass this stage of preclinical testing.
“This validates our previous rodent data and positions our vaccine in a favorable light for anticipated clinical evaluation,” said study leader Kim Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI.
This research was published recently in the Journal of the American Chemical Society. The primate experiments were led by researchers at Virginia Commonwealth University.
The vaccine works by exposing the immune system to a part of the heroin molecule’s telltale structure. This teaches the immune system to produce antibodies against heroin and its psychoactive products. The antibodies neutralize heroin molecules, blocking them from reaching the brain to cause a feeling of euphoria.
Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use. In recent years, public health officials around the world have labeled heroin use as an epidemic.
The Janda Laboratory at TSRI has been working on their heroin vaccine for over eight years; the researchers had previously tested vaccine candidates under laboratory conditions and in rodents, where the strategy proved effective for neutralizing heroin.
For the new study in rhesus monkeys, the researchers redesigned their vaccine candidate to more closely resemble heroin, with the goal of better stimulating the immune system to attack this opioid.
The researchers found that the four primates that were given three doses of this vaccine showed an effective immune response and could neutralize varying doses of heroin. This effect was most acute in the first month after vaccination but lasted for over eight months. The researchers also found no negative side effects from the vaccine.
“We believe this vaccine candidate will prove safe for human trials,” Janda said. He pointed out that the components of the vaccine have either already been approved by the FDA or have passed safety tests in previous clinical trials.
Interestingly, two of the four primates tested had been pre-vaccinated with the same vaccine candidate for a more basic pilot study seven months prior to the experiment in this study. The researchers found that these two primates showed a much higher response to the vaccine in the second round of experiments. This suggested their antibody-producing cells held an immunological “memory” of the vaccine. If this effect holds true in humans, a recovering addict would have long-term immunity to heroin.
“We were really encouraged to see the vaccine produce such lasting effects in non-human primate models,” said Bremer.
This is the first vaccine against heroin to succeed in primate models. Vaccines against other drugs of abuse have been tested in humans without first completing non-human primate trials—and failed. Bremer said the new heroin vaccine is different because the researchers took a closer look at the chemistry of the vaccine, studying how well antibodies elicited by the vaccine could bind to drug molecules. “These steps let us put our best foot forward when we went into the primate study,” Bremer said.
The researchers noted that this vaccine candidate works only against heroin and not other opioid-based pain killers or medications for treating opioid addiction or overdose, leaving those open for use in emergency medical situations and for prescription medicines and substance use disorders.
The next step in this research will be to license the vaccine to an outside company for partnering in clinical trials.
The Latest on: Heroin vaccine
Experts query case for GlaxoSmithKline's new 3-in-1 lung drug
on April 18, 2018 at 8:55 pm
The British drugmaker views Trelegy as a critical new product, along with shingles vaccine Shingrix, as it seeks to fill a revenue gap left by falling sales of the older lung drug Advair, which could face U.S. generic competition this year. (Reporting by ... […]
Researchers discover unique protein in malaria parasite that could be new drug target
on April 18, 2018 at 6:08 pm
Additionally, a strong effort is being made at Radboud university medical center and other institutes to develop a vaccine. Effective policy has nearly ... that could be used as a target for such a new drug. Powerhouses of the cell Almost all cells in ... […]
Gates Sees Vaccine Technology Promise as Drug Resistance Rises
on April 18, 2018 at 10:06 am
Billionaire philanthropist Bill Gates sees emerging vaccine technologies as one of the most promising realms in the pursuit of new medicines amid the rising threat of drug-resistant strains of deadly diseases. Vaccines that use a mirror image of DNA to ... […]
FDA Launches Investigation Regarding Professor Who Gave Unauthorized Herpes Vaccine to Patients in Caribbean and Illinois: Report
on April 17, 2018 at 1:57 pm
The Food and Drug Administration has started an investigation into a Southern Illinois University professor who injected patients with an experimental herpes vaccine. Kaiser Health News, which broke the story, reports that SIU professor William Halford ... […]
Emergent BioSolutions to enter 5 new countries with anthrax vaccine
on April 16, 2018 at 11:15 am
But for now, BioThrax is the only anthrax vaccine licensed by the Food and Drug Administration to the U.S. government, for pre-exposure protection from anthrax-causing bacteria. BioThrax sales account for a significant chunk of Emergent’s revenue ... […]
via Google News and Bing News